SCHEMBL5483571

SCHEMBL5483571

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3oc(Cl)cc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
KDM4E B2RXH2 5/20 0.37
GLA P06280 4/20 0.37
GAA P10253 3/20 0.37
CA12 O43570 2/20 0.37
CA9 Q16790 2/20 0.37
POLB P06746 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 4/20 0.36
GAPDH P04406 1/20 0.36
ALDH1A1 P00352 3/20 0.35
TP53 P04637 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PKM P14618 1/20 0.34
TTR P02766 1/20 0.34
CYP3A4 P08684 1/20 0.34
FLT3 P36888 1/20 0.34
HTT P42858 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5488975 0.86 MAPT (0.43) MAPTKDM4EGLAGAACA12
SCHEMBL5481283 0.78 MAPT (0.60) MAPTKDM4EGLAGAACA12
SCHEMBL5481754 0.76 HTR6 (0.40) MAPTKDM4ETDP1LMNAALDH1A1
SCHEMBL5482736 0.75 MAPT (0.56) MAPTKDM4EGLAGAACA12
SCHEMBL5482053 0.75 MAPT (0.56) MAPTKDM4EGLAGAAPOLB
SCHEMBL5483660 0.74 MAPT (0.70) MAPTKDM4EGLAGAAPOLB
SCHEMBL30226150 0.74 MAPT (0.70) MAPTKDM4EGLAGAACA12
Oxyphenisatin Acetate SCHEMBL29737232 0.72 MAPT (1.00) MAPTGAALMNAALDH1A1SMN1; SMN2
Oxyphenisatin Acetate SCHEMBL7528210 0.72 MAPT (1.00) MAPTGAALMNAALDH1A1SMN1; SMN2
Oxyphenisatin Acetate SCHEMBL555117 0.72 MAPT (1.00) MAPTGAALMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885KDM4E 420/4885GLA 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.